drugset / Trial / NCT05657704
Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol
Phase 4
Unknown
300 enrolled
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Hospital San Carlos, Madrid · collabHospital Universitario Fundación Jiménez Díaz · collabHospital Universitario La Paz · collabHospital Universitario Ramon y Cajal · collabHospital Universitario San Juan de Alicante · collabHospital Universitario de Burgos · collabPuerta de Hierro University Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized clinical trial to evaluate the utility of CYP2D6 genotyping to improve the efficacy and safety of tramadol in the treatment of acute postoperative pain. Phase IV and low-intervention trial To evaluate if the implementation of pharmacogenetics in clinical practice can help to improve the treatment of acute pain, increasing efficacy and reducing adverse reactions. The main evaluation variable: This is a simple study, which does not differ from standard clinical practice and therefore we do not expect early ending of the study.
Timeline
- Start
- 2022-10-05
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexketoprofen | Small molecule | 25 mg | — |
| Subject | Tramadol | Other / unclassified | 50 mg | — |
| Subject | Tramadol | Other / unclassified | 100 mg | — |
Indications
No indication recorded.